Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)

NCT06016738 is registered in ClinicalTrials.gov with Olema Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06016738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06016738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Lead sponsor
Olema Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 16, 2023
Completion date
February 29, 2028
Enrollment
510 (estimated)
Sites
233

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, breast cancer, er positive breast cancer, her2 negative breast carcinoma, metastatic breast cancer